Home LiteratureArticle Details
PMID: 22308357 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.

Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T

Abstract

Smoldering inflammation often increases the risk of progression for malignant tumors and simultaneously matures myeloid dendritic cells (mDCs) for cell-mediated immunity. PolyI:C, a dsRNA analog, is reported to induce inflammation and potent antitumor immune responses via the Toll-like receptor 3/Toll-IL-1 receptor domain-containing adaptor molecule 1 (TICAM-1) and melanoma differentiation-associated protein 5/IFN-β promoter stimulator 1 (IPS-1) pathways in mDCs to drive activation of natural killer cells and cytotoxic T lymphocytes. Here, we found that i.p. or s.c. injection of polyI:C to Lewis lung carcinoma tumor-implant mice resulted in tumor regression by converting tumor-supporting macrophages (Mfs) to tumor suppressors. F4/80(+)/Gr1(-) Mfs infiltrating the tumor respond to polyI:C to rapidly produce inflammatory cytokines and thereafter accelerate M1 polarization. TNF-α was increased within 1 h in both tumor and serum upon polyI:C injection into tumor-bearing mice, followed by tumor hemorrhagic necrosis and growth suppression. These tumor responses were abolished in TNF-α(-/-) mice. Furthermore, F4/80(+) Mfs in tumors extracted from polyI:C-injected mice sustained Lewis lung carcinoma cytotoxic activity, and this activity was partly abrogated by anti-TNF-α Ab. Genes for supporting M1 polarization were subsequently up-regulated in the tumor-infiltrating Mfs. These responses were completely abrogated in TICAM-1(-/-) mice, and unaffected in myeloid differentiation factor 88(-/-) and IPS-1(-/-) mice. Thus, the TICAM-1 pathway is not only important to mature mDCs for cross-priming and natural killer cell activation in the induction of tumor immunity, but also critically engaged in tumor suppression by converting tumor-supporting Mfs to those with tumoricidal properties.

MeSH Terms
Adaptor Proteins, Signal Transducing/metabolism Adaptor Proteins, Vesicular Transport/metabolism Animals Antineoplastic Agents/pharmacology Carcinoma, Lewis Lung/immunology,pathology Cell Polarity/drug effects,immunology Cytotoxicity, Immunologic/drug effects Macrophages/drug effects,immunology,pathology Mice Myeloid Cells/immunology,pathology Poly I-C/pharmacology Signal Transduction/drug effects,immunology Toll-Like Receptor 3/immunology Tumor Necrosis Factor-alpha/metabolism
Chemicals
Adaptor Proteins, Signal Transducing Adaptor Proteins, Vesicular Transport Antineoplastic Agents IPS-1 protein, mouse TICAM-1 protein, mouse Toll-Like Receptor 3 Tumor Necrosis Factor-alpha Poly I-C
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Shime Hiroaki
Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.
Matsumoto Misako
Oshiumi Hiroyuki
Tanaka Shinya
Nakane Akio
Iwakura Yoichiro
Tahara Hideaki
Inoue Norimitsu
Seya Tsukasa
References (55)
55 references, click to expand
  1. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells.
    J Exp Med. 2009 Dec 21;206(13):2967-76 PMID: 19995959
  2. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
    J Immunol. 1995 Aug 1;155(3):1393-403 PMID: 7636204
  3. Oncolytic viral therapies - the clinical experience.
    Oncogene. 2005 Nov 21;24(52):7802-16 PMID: 16299539
  4. Diminished expression of transcription factors nuclear factor kappaB and CCAAT/enhancer binding protein underlies a novel tumor evasion mechanism affecting macrophages of mammary tumor-bearing mice.
    Cancer Res. 2005 Nov 15;65(22):10578-84 PMID: 16288051
  5. Molecular mechanisms regulating TNF-alpha production by tumor-associated macrophages.
    Cancer Lett. 1997 Jan 1;111(1-2):27-37 PMID: 9022125
  6. The use of dendritic cells in cancer immunotherapy.
    Curr Opin Immunol. 2003 Apr;15(2):138-47 PMID: 12633662
  7. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection.
    Nat Immunol. 2010 Oct;11(10):936-44 PMID: 20729857
  8. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).
    Blood. 2006 Mar 1;107(5):2112-22 PMID: 16269622
  9. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages.
    J Immunol. 2000 Jan 15;164(2):762-7 PMID: 10623821
  10. Tumour necrosis factor and cancer.
    Nat Rev Cancer. 2009 May;9(5):361-71 PMID: 19343034
  11. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation.
    J Exp Med. 2010 Nov 22;207(12):2675-87 PMID: 21059856
  12. An endotoxin-induced serum factor that causes necrosis of tumors.
    Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 PMID: 1103152
  13. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis.
    Cancer Res. 2008 Dec 15;68(24):10060-7 PMID: 19074871
  14. Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator.
    Nature. 1969 Aug 16;223(5207):715-7 PMID: 5805520
  15. Inhibition of tumor growth by polyinosinic-polycytidylic acid.
    Proc Natl Acad Sci U S A. 1969 Feb;62(2):357-61 PMID: 4894326
  16. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.
    Nat Immunol. 2011 Mar;12(3):231-8 PMID: 21240265
  17. Regulation of adaptive immunity by the innate immune system.
    Science. 2010 Jan 15;327(5963):291-5 PMID: 20075244
  18. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer.
    J Exp Med. 2004 Nov 15;200(10):1325-35 PMID: 15545356
  19. Pattern recognition receptors and inflammation.
    Cell. 2010 Mar 19;140(6):805-20 PMID: 20303872
  20. Inflammation and cancer: the oncogene-driven connection.
    Cancer Lett. 2008 Aug 28;267(2):262-70 PMID: 18502035
  21. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction.
    J Immunol. 2006 Dec 15;177(12):8676-83 PMID: 17142768
  22. Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation.
    J Biol Chem. 2011 Mar 25;286(12):10702-11 PMID: 21266579
  23. Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.
    Cancer Res. 1985 Mar;45(3):1058-65 PMID: 3155990
  24. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.
    J Immunol. 2011 Feb 15;186(4):2422-9 PMID: 21242525
  25. Regression of Burkitt's lymphoma in association with measles infection.
    Lancet. 1971 Jul 10;2(7715):105-6 PMID: 4103972
  26. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-"pan" RAE-1 antibody confer tumor susceptibility to NK cells.
    Biochem Biophys Res Commun. 2002 Jan 11;290(1):140-5 PMID: 11779145
  27. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
    N Engl J Med. 2007 May 24;356(21):2131-42 PMID: 17522398
  28. Regulation of the CTL response by macrophage migration inhibitory factor.
    J Immunol. 2001 Jan 15;166(2):747-53 PMID: 11145646
  29. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.
    Cell. 2006 Jan 27;124(2):263-6 PMID: 16439202
  30. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.
    J Immunol. 2005 Sep 1;175(5):2851-8 PMID: 16116171
  31. Alternative activation of macrophages: an immunologic functional perspective.
    Annu Rev Immunol. 2009;27:451-83 PMID: 19105661
  32. Antiviral responses induced by the TLR3 pathway.
    Rev Med Virol. 2011 Mar;21(2):67-77 PMID: 21312311
  33. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing.
    Cell. 2007 Sep 21;130(6):1083-94 PMID: 17825402
  34. The chemokine system in diverse forms of macrophage activation and polarization.
    Trends Immunol. 2004 Dec;25(12):677-86 PMID: 15530839
  35. TLR3: interferon induction by double-stranded RNA including poly(I:C).
    Adv Drug Deliv Rev. 2008 Apr 29;60(7):805-12 PMID: 18262679
  36. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells.
    Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):252-7 PMID: 17190817
  37. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways.
    J Immunol. 2009 Aug 15;183(4):2522-8 PMID: 19635904
  38. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
    Science. 2007 Jun 15;316(5831):1628-32 PMID: 17569868
  39. Toll-like receptor 3 promotes cross-priming to virus-infected cells.
    Nature. 2005 Feb 24;433(7028):887-92 PMID: 15711573
  40. Paradoxical roles of the immune system during cancer development.
    Nat Rev Cancer. 2006 Jan;6(1):24-37 PMID: 16397525
  41. Virus-induced sarcoma of mice: inhibition by a synthetic polyribonucleotide complex.
    Proc Natl Acad Sci U S A. 1969 Apr;62(4):1046-51 PMID: 5256404
  42. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.
    Science. 2007 Jul 6;317(5834):124-7 PMID: 17615359
  43. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.
    Nat Immunol. 2003 Feb;4(2):161-7 PMID: 12539043
  44. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor.
    Int J Cancer. 2007 Jun 1;120(11):2474-80 PMID: 17330231
  45. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer.
    Cancer Immunol Immunother. 2009 Aug;58(8):1175-84 PMID: 19184005
  46. New vistas on macrophage differentiation and activation.
    Eur J Immunol. 2007 Jan;37(1):14-6 PMID: 17183610
  47. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice.
    Cancer Res. 2004 Jan 15;64(2):757-64 PMID: 14744795
  48. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors.
    FEBS Lett. 2007 Jul 24;581(18):3334-40 PMID: 17601575
  49. RNA viruses as virotherapy agents.
    Cancer Gene Ther. 2002 Dec;9(12):961-6 PMID: 12522435
  50. Tumor necrosis factor, cancer and anticancer therapy.
    Cytokine Growth Factor Rev. 2005 Feb;16(1):35-53 PMID: 15733831
  51. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
    J Exp Med. 2009 Jul 6;206(7):1589-602 PMID: 19564349
  52. Poly I:C activated macrophages are tumoricidal for TNF-alpha-resistant 3LL tumor cells.
    J Immunol. 1990 Jun 1;144(11):4477-86 PMID: 2111350
  53. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
    Nat Immunol. 2010 Oct;11(10):889-96 PMID: 20856220
  54. The role of myeloid cells in the promotion of tumour angiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):618-31 PMID: 18633355
  55. Immunity, inflammation, and cancer.
    Cell. 2010 Mar 19;140(6):883-99 PMID: 20303878
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2012-02-07
Epub
2012-00-19
Pages
2066-71
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC3277567
Subset
IM
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com